Rx Product News (October 2017)

OCTOBER 27, 2017

DUZALLO
MANUFACTURED BY:
Ironwood Pharmaceuticals
INDICATION: The FDA has approved lesinurad and allopurinol (Duzallo) fixed-dose combination treatment for hyperuricemia in patients with uncontrolled gout.
DOSAGE: Tablet: 200 mg lesinurad and 300 mg allopurinol, or 200 mg lesinurad and 200 mg allopurinol
FOR MORE INFORMATION: ironwoodpharma.com


BESPONSA
MANUFACTURED BY:
Pfizer
INDICATION: The FDA has approved inotuzumab ozogamicin (Besponsa) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
DOSAGE: Injection: 0.9 mg
FOR MORE INFORMATION: pfizer.com


MAVYRET
MANUFACTURED BY:
AbbVie
INDICATION: The FDA has approved glecaprevir/pibrentasvir (Mavyret), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus infection across all major genotypes.
DOSAGE: Tablet: 100 mg glecaprevir and 40 mg pibrentasvir
FOR MORE INFORMATION: abbvie.com


VYXEOS
MANUFACTURED BY:
Jazz Pharmaceuticals
INDICATION: The FDA has approved daunorubicin and cytarabine (Vyxeos) liposome for injection to treat adults with 2 types of acute myeloid leukemia (AML). Vyxeos is indicated to treat adults with newly diagnosed therapy related-AML or AML myelodyplasia-related change.
DOSAGE: Injection: 44 mg daunorubicin and 100 mg cytarabine
FOR MORE INFORMATION: jazzpharma.com

SHARE THIS SHARE THIS
0
Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.